InsiderTrades

Form 4 for XYL Xylem Inc.

Accepted 2024-06-11 00:00:00 ET · period of report 2024-06-10 · accession 0001562180-24-004944 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-06-11 2024-06-10 XYL McShane Geri-Michelle VP, CAO, Ctrl M - OptEx $74.71 +1,766 5,067 +53% +$131.9K
D 2024-06-11 2024-06-10 XYL McShane Geri-Michelle VP, CAO, Ctrl S - Sale+OE $138.63 -2,278 3,536 -39% -$315.8K
DM 2024-06-11 2024-06-10 XYL McShane Geri-Michelle VP, CAO, Ctrl M - OptEx $0.00 -1,766 747 -70% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-06-10 M A 747 $74.07 5,814 D — —
2 Common Common Stock 2024-06-10 M A 1,019 $75.18 5,067 D — —
3 Common Common Stock 2024-06-10 S D 2,278 $138.63 3,536 D — — (F1) This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 2,278 Shares were executed at a range of prices from $138.62 to $138.65. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price.
4 Derivative Non-Qualified Stock Option (Right to Buy) 2024-06-10 M D 1,019 $0.00 1,019 D $75.18 · — to 2028-02-21 1,019 Common Stock (F2) The February 21, 2018 option grant vested one third on February 21, 2019, February 21, 2020, and February 21, 2021.
5 Derivative Non-Qualified Stock Option (Right to Buy) 2024-06-10 M D 747 $0.00 747 D $74.07 · — to 2029-02-20 747 Common Stock (F3) The February 20, 2019 option grant vested one third on February 20, 2020, February 20, 2021, and February 20, 2022.